Immatics (IMTX) and Bristol Myers Squibb (BMY) Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/16/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. DVLT
10. ADYYF

Go back to Immatics (IMTX) and Bristol Myers Squibb (BMY) Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs

Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs

June 2, 2022 6:59 AM EDT

New multi-program collaboration to develop allogeneic TCR-T/CAR-T programs brings together Immatics allogeneic gamma delta T cell therapy platform ACTallo® with Bristol Myers Squibbs technologies and oncology drug development expertise
Immatics to receive upfront payment of $60 million and additional milestone payments of up to $700 million per program plus tiered royalty payments of up to low double-digit percentages on net product sales across multiple programs under the new collaboration
Per 2019 agreement, Bristol Myers Squibb to also add one additional autologous TCR-T target where Immatics will... More